Cargando…
Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease
BACKGROUND: The recent promise of disease-modifying therapies for Alzheimer’s disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the development of novel blood-based biomarkers for AD have revealed that plasma lev...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652927/ https://www.ncbi.nlm.nih.gov/pubmed/36371232 http://dx.doi.org/10.1186/s13195-022-01116-2 |